{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:30:02Z","timestamp":1789615802970,"version":"build-2803163510"},"reference-count":143,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Coronary atherosclerosis is increasingly recognized as a chronic, maladaptive inflammatory disease initiated by arterial retention of apolipoprotein B (apoB)\u2013containing lipoproteins and amplified by innate and adaptive immune responses. Although low-density lipoprotein cholesterol (LDL-C) remains a central causal factor, substantial residual risk persists despite intensive LDL-C lowering, emphasizing the clinical relevance of residual inflammatory risk and additional atherogenic lipid metrics such as apolipoprotein B (apoB), remnant cholesterol, small dense LDL, and lipoprotein(a) [Lp(a)]. Landmark outcome trials validate both paradigms: potent lipid-lowering therapies reduce major adverse cardiovascular events, and targeted anti-inflammatory therapies such as IL-1\u03b2 inhibition and low-dose colchicine reduce recurrent events without altering LDL-C, establishing inflammation as a modifiable driver of coronary risk. This review integrates mechanistic evidence linking lipids and inflammation across the atherosclerotic continuum\u2014from endothelial activation and leukocyte recruitment to plaque destabilization and thrombosis\u2014while critically appraising biomarkers, imaging approaches, and therapeutic strategies. We propose a practical dual-axis framework integrating residual cholesterol and inflammatory risks to guide combined therapy and highlight future directions including genetics-informed lipid management [notably Lp(a)], inflammation-resolution biology, and precision targeting of upstream inflammatory pathways such as IL-6 signaling.<\/jats:p>","DOI":"10.3389\/fcvm.2026.1790509","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T04:38:15Z","timestamp":1776832695000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Inflammation and lipid-related determinants in coronary atherosclerosis: mechanisms, biomarkers, and therapeutic implications"],"prefix":"10.3389","volume":"13","author":[{"given":"Fubo","family":"Zhang","sequence":"first","affiliation":[{"name":"The First School of Clinical Medicine, Faculty of Medicine, Yangzhou University","place":["Yangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingchi","family":"Liao","sequence":"additional","affiliation":[{"name":"Northern Jiangsu People's Hospital Affiliated to Yangzhou University","place":["Yangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis\u2014an inflammatory disease","volume":"340","author":"Ross","year":"1999","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/nature01323","article-title":"Inflammation in atherosclerosis","volume":"420","author":"Libby","year":"2002","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1056\/NEJMra043430","article-title":"Inflammation, atherosclerosis, and coronary artery disease","volume":"352","author":"Hansson","year":"2005","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-Dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","article-title":"Apolipoprotein B particles and cardiovascular disease: a narrative review","volume":"4","author":"Sniderman","year":"2019","journal-title":"JAMA Cardiol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1001\/jamacardio.2021.5083","article-title":"Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis: distinguishing between particle concentration, type, and content","volume":"7","author":"Marston","year":"2022","journal-title":"JAMA Cardiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"B18","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/nri3670","article-title":"Pro-resolving lipid mediators and the resolution of inflammation","volume":"14","author":"Serhan","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1161\/CIRCRESAHA.121.319833","article-title":"Inflammation resolution in atherosclerosis","volume":"130","author":"Van der Vorst","year":"2022","journal-title":"Circ Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1016\/j.jacc.2021.01.027","article-title":"Apolipoprotein B and non-HDL cholesterol better reflect residual risk than LDL cholesterol in statin-treated patients","volume":"77","author":"Johannesen","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1097\/MOL.0000000000000330","article-title":"The central role of arterial retention of cholesterol-rich apoB-containing lipoproteins in atherogenesis","volume":"27","author":"Boren","year":"2016","journal-title":"Curr Opin Lipidol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.ajpath.2017.01.018","article-title":"Boosting inflammation resolution in atherosclerosis: the next frontier for therapy","volume":"187","author":"Fredman","year":"2017","journal-title":"Am J Pathol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41569-019-0169-2","article-title":"Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities","volume":"16","author":"B\u00e4ck","year":"2019","journal-title":"Nat Rev Cardiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S0140-6736(14)61177-6","article-title":"Triglycerides and cardiovascular disease","volume":"384","author":"Nordestgaard","year":"2014","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41569-019-0298-5","article-title":"Defective efferocytosis in atherosclerosis","volume":"17","author":"Yurdagul","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nri2675","article-title":"Macrophage death and defective efferocytosis in atherosclerosis","volume":"10","author":"Tabas","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.coi.2012.01.010","article-title":"The CD47\u2013SIRP\u03b1 pathway in cancer immune evasion and therapeutic implications (conceptual relevance to efferocytosis)","volume":"24","author":"Chao","year":"2012","journal-title":"Curr Opin Immunol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1161\/CIRCULATIONAHA.116.025684","article-title":"The role of efferocytosis in atherosclerosis","volume":"135","author":"Kojima","year":"2017","journal-title":"Circulation"},{"key":"B29","author":"Sadaf","year":"2025"},{"key":"B30","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1161\/CIRCRESAHA.116.309756","article-title":"Neutrophil extracellular traps in atherosclerosis","volume":"120","author":"D\u00f6ring","year":"2017","journal-title":"Circ Res"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2768","DOI":"10.1182\/blood-2013-10-463646","article-title":"Thrombosis: tangled up in NETs","volume":"123","author":"Martinod","year":"2014","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/nri3345","article-title":"Thrombosis as an intravascular effector of innate immunity","volume":"13","author":"Engelmann","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"15880","DOI":"10.1073\/pnas.1005743107","article-title":"Extracellular DNA traps promote thrombosis","volume":"107","author":"Fuchs","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1038\/s12276-024-01281-4","article-title":"Neutrophil extracellular traps mediate the crosstalk between plaque microenvironment and unstable carotid plaque formation","volume":"56","author":"Cao","year":"2024","journal-title":"Exp Mol Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","article-title":"The interleukin-6 receptor as a target for prevention of coronary heart disease: Mendelian randomisation analysis","volume":"379","year":"2012","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1038\/nature08938","article-title":"NLRP3 In ammasomes are required for atherogenesis","volume":"464","author":"Duewell","year":"2010","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1161\/CIRCRESAHA.118.311361","article-title":"NLRP3 Inflammasome and the IL-1 pathway in atherosclerosis","volume":"122","author":"Grebe","year":"2018","journal-title":"Circ Res"},{"key":"B38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1001\/jamacardio.2022.4277","article-title":"Ziltivekimab and neutrophil\u2013lymphocyte ratio: rESCUE secondary analysis","volume":"8","author":"Adamstein","year":"2023","journal-title":"JAMA Cardiol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1001\/jamacardio.2025.4491","article-title":"Rationale, design, and baseline clinical characteristics of the ziltivekimab cardiovascular outcomes trial: interleukin-6 inhibition and atherosclerotic event rate reduction","volume":"11","author":"Ridker","year":"2026","journal-title":"JAMA Cardiol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/j.cell.2017.12.013","article-title":"Western diet triggers NLRP3-dependent innate immune reprogramming","volume":"172","author":"Christ","year":"2018","journal-title":"Cell"},{"key":"B41","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41573-021-00198-1","article-title":"Targeting inflammation in atherosclerosis\u2014from experimental insights to the clinic","volume":"20","author":"Soehnlein","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1161\/CIRCRESAHA.120.315937","article-title":"Interleukin-1 and the in ammasome as therapeutic targets in cardiovascular disease","volume":"126","author":"Abbate","year":"2020","journal-title":"Circ Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/eurheartj\/ehaa099","article-title":"Targeting cardiovascular in ammation: next steps in clinical translation","volume":"42","author":"Lawler","year":"2021","journal-title":"Eur Heart J"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride lowering with pemafibrate (PROMINENT)","volume":"387","author":"Pradhan A","year":"2022","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"STRENGTH","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"key":"B46","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1097\/HCO.0000000000000678","article-title":"Cardiovascular risk reduction with icosapent ethyl","volume":"34","author":"Patel","year":"2019","journal-title":"Curr Opin Cardiol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","year":"2014","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"B49","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1056\/NEJMoa1002358","article-title":"A prospective natural-history study of coronary atherosclerosis (PROSPECT)","volume":"364","author":"Stone","year":"2011","journal-title":"N Engl J Med"},{"key":"B50","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1161\/CIRCRESAHA.115.306361","article-title":"VSMCs in atherosclerosis","volume":"118","author":"Bennett","year":"2016","journal-title":"Circ Res"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.it.2019.04.012","article-title":"Neutrophil diversity in health and disease","volume":"40","author":"Silvestre-Roig","year":"2019","journal-title":"Trends Immunol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/nri.2017.10","article-title":"Neutrophils as protagonists and targets in chronic inflammation","volume":"17","author":"Soehnlein","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1097\/MOL.0000000000000093","article-title":"Remnant cholesterol and ischemic heart disease","volume":"25","author":"Varbo","year":"2014","journal-title":"Curr Opin Lipidol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.jacc.2012.08.1026","article-title":"Remnant cholesterol as a causal risk factor for ischemic heart disease","volume":"61","author":"Varbo","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in ASCVD and aortic stenosis: 2022 EAS consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"B57","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jacc.2016.11.042","article-title":"A test in context: lipoprotein(a)","volume":"69","author":"Tsimikas","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and risk of coronary heart disease","volume":"302","year":"2009","journal-title":"JAMA"},{"key":"B59","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1056\/NEJMoa1905239","article-title":"Lipoprotein(a) reduction in persons with cardiovascular disease","volume":"382","author":"Tsimikas","year":"2020","journal-title":"N Engl J Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease","volume":"387","author":"O\u2019Donoghue","year":"2022","journal-title":"N Engl J Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/nri2156","article-title":"Leukocyte adhesion cascade updated","volume":"7","author":"Ley","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1161\/01.RES.0000146672.10582.17","article-title":"Chemokines in the pathogenesis of vascular disease","volume":"95","author":"Charo","year":"2004","journal-title":"Circ Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1194\/jlr.R060582","article-title":"Lipoprotein(a): truly a direct prothrombotic factor in cardiovascular disease?","volume":"57","author":"Boffa","year":"2016","journal-title":"J Lipid Res"},{"key":"B64","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Erqou","year":"2009","journal-title":"JAMA"},{"key":"B65","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Elevated lipoprotein(a) and risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"B66","doi-asserted-by":"publisher","first-page":"C13","DOI":"10.1016\/j.jacc.2005.10.065","article-title":"Pathology of the vulnerable plaque","volume":"47","author":"Virmani","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/CIR.0000000000000625","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"B68","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC guideline on CVD prevention","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur Heart J"},{"key":"B69","doi-asserted-by":"publisher","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","article-title":"Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies","volume":"42","author":"Ginsberg","year":"2021","journal-title":"Eur Heart J"},{"key":"B70","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1161\/CIRCRESAHA.115.306249","article-title":"Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease: new insights","volume":"118","author":"Nordestgaard","year":"2016","journal-title":"Circ Res"},{"key":"B71","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"REDUCE-IT","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehaa652","article-title":"EVAPORATE","volume":"41","author":"Budoff","year":"2020","journal-title":"Eur Heart J"},{"key":"B73","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.15420\/ecr.2020.49","article-title":"The role of C-reactive protein in patient risk stratification and treatment","volume":"16","author":"Arroyo-Espliguero","year":"2021","journal-title":"Eur Cardiol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus (ACCORD lipid)","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/jama.2022.5218","article-title":"Alirocumab in acute myocardial infarction and coronary atherosclerosis (PACMAN-AMI)","volume":"327","author":"R\u00e4ber","year":"2022","journal-title":"JAMA"},{"key":"B76","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"Evolocumab and coronary plaque regression (GLAGOV)","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e1082","DOI":"10.1161\/CIR.0000000000000625","article-title":"2018 AHA\/ACC guideline on the management of blood cholesterol","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events (ODYSSEY LONG TERM)","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1016\/j.jacc.2014.03.018","article-title":"Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 trial","volume":"63","author":"Koren","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","article-title":"Inclisiran in patients with heterozygous familial hypercholesterolemia (ORION-9)","volume":"382","author":"Raal","year":"2020","journal-title":"N Engl J Med"},{"key":"B81","doi-asserted-by":"publisher","first-page":"6296","DOI":"10.1038\/s41467-020-20141-z","article-title":"Macrophage ATP citrate lyase deficiency stabilizes atherosclerotic plaques","volume":"11","author":"Baardman","year":"2020","journal-title":"Nat Commun"},{"key":"B82","author":"Sadaf","year":"2025"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1161\/CIRCULATIONAHA.120.050771","article-title":"Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial","volume":"142","author":"Tong","year":"2020","journal-title":"Circulation"},{"key":"B84","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ahj.2022.06.002","article-title":"Select drug-drug interactions with colchicine and cardiovascular medications: a review","volume":"252","author":"Dixon","year":"2022","journal-title":"Am Heart J"},{"key":"B85","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and ASCVD risk","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"key":"B86","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"key":"B87","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"},{"key":"B88","doi-asserted-by":"publisher","first-page":"aaf1098","DOI":"10.1126\/science.aaf1098","article-title":"Trained immunity: a program of innate immune memory in health and disease","volume":"352","author":"Netea","year":"2016","journal-title":"Science"},{"key":"B89","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41577-020-0285-6","article-title":"Defining trained immunity and its role in health and disease","volume":"20","author":"Netea","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein (JUPITER)","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"B91","doi-asserted-by":"publisher","first-page":"e0225559","DOI":"10.1371\/journal.pone.0225559","article-title":"sdLDL and CHD: meta-analysis","volume":"15","author":"Liou","year":"2020","journal-title":"PLoS One"},{"key":"B92","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"B93","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/j.jacc.2018.06.078","article-title":"Effect of evolocumab on coronary plaque composition","volume":"72","author":"Nicholls","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1093\/eurheartj\/ehw024","article-title":"Residual inflammatory risk: addressable and actionable","volume":"37","author":"Ridker","year":"2016","journal-title":"Eur Heart J"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1056\/NEJMoa1109400","article-title":"Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk","volume":"368","author":"Tang","year":"2013","journal-title":"N Engl J Med"},{"key":"B96","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.cell.2011.04.005","article-title":"Macrophages in atherosclerosis","volume":"145","author":"Moore","year":"2011","journal-title":"Cell"},{"key":"B97","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1056\/NEJMoa1001689","article-title":"Cholesterol ef ux and atherosclerosis","volume":"364","author":"Khera","year":"2011","journal-title":"N Engl J Med"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia (WOSCOPS)","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"B99","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/s11883-014-0465-6","article-title":"Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances","volume":"17","author":"Stefanutti","year":"2015","journal-title":"Curr Atheroscler Rep"},{"key":"B100","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/joim.12862","article-title":"Anti-inflammatory therapy for atherosclerosis: interpreting divergent results from the CANTOS and CIRT clinical trials","volume":"285","author":"Ridker","year":"2019","journal-title":"J Intern Med"},{"key":"B101","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1093\/eurheartj\/ehz520","article-title":"Relationship between coronary plaque morphology of the left anterior descending artery and 12 months clinical outcome: the CLIMA study","volume":"41","author":"Prati","year":"2020","journal-title":"Eur Heart J"},{"key":"B102","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1161\/CIRCRESAHA.115.306256","article-title":"Macrophage phenotype and function in atherosclerosis","volume":"118","author":"Tabas","year":"2016","journal-title":"Circ Res"},{"key":"B103","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL Ef ux capacity and incident events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N Engl J Med"},{"key":"B104","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20,536 high-risk individuals","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"B105","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events (ILLUMINATE)","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"B106","doi-asserted-by":"publisher","first-page":"2331","DOI":"10.1161\/CIR.0b013e3181dbece1","article-title":"Particulate matter air pollution and cardiovascular disease","volume":"121","author":"Brook","year":"2010","journal-title":"Circulation"},{"key":"B107","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1161\/CIRCRESAHA.115.306301","article-title":"Endothelial dysfunction and atherosclerosis","volume":"118","author":"Gimbrone","year":"2016","journal-title":"Circ Res"},{"key":"B108","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1001\/jama.2022.5212","article-title":"PACMAN-AMI","volume":"327","author":"R\u00e4ber","year":"2022","journal-title":"JAMA"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes (PROVE IT\u2013TIMI 22)","volume":"350","author":"Cannon","year":"2004","journal-title":"N Engl J Med"},{"key":"B110","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome (dal-OUTCOMES)","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"B111","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"key":"B112","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1161\/CIRCRESAHA.117.306458","article-title":"Environmental determinants of cardiovascular disease","volume":"121","author":"Bhatnagar","year":"2017","journal-title":"Circ Res"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1172\/JCI9253","article-title":"Targeted disruption of CD36 protects against atherosclerosis in mice","volume":"105","author":"Febbraio","year":"2000","journal-title":"J Clin Invest"},{"key":"B114","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1001\/jama.2016.16951","article-title":"GLAGOV","volume":"316","author":"Nicholls","year":"2016","journal-title":"JAMA"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease (TNT)","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and cardiovascular outcomes in high-risk vascular disease (ACCELERATE)","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med"},{"key":"B117","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1056\/NEJMoa1200303","article-title":"Primary prevention of cardiovascular disease with a Mediterranean diet (PREDIMED)","volume":"368","author":"Estruch","year":"2013","journal-title":"N Engl J Med"},{"key":"B118","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1126\/science.aag1381","article-title":"TET2 Deficiency accelerates atherosclerosis","volume":"355","author":"Fuster","year":"2017","journal-title":"Science"},{"key":"B119","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs usualdose simvastatin for secondary prevention (IDEAL)","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"B120","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of anacetrapib in patients with atherosclerotic vascular disease (REVEAL)","volume":"377","author":"Bowman","year":"2017","journal-title":"N Engl J Med"},{"key":"B121","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1056\/NEJM200101043440101","article-title":"Effects on blood pressure of reduced dietary sodium and the DASH diet","volume":"344","author":"Sacks","year":"2001","journal-title":"N Engl J Med"},{"key":"B122","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/eurheartj\/eht004","article-title":"Pathologists\u2019 view of acute coronary syndromes","volume":"34","author":"Falk","year":"2013","journal-title":"Eur Heart J"},{"key":"B123","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nm.3145","article-title":"Microbiota metabolism of L-carnitine and atherosclerosis","volume":"19","author":"Koeth","year":"2013","journal-title":"Nat Med"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","year":"2005","journal-title":"Lancet"},{"key":"B125","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy (AIM-HIGH)","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"B126","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1161\/01.RES.0000260802.75766.00","article-title":"Monocyte\/macrophage suppression in CD11b diphtheria toxin receptor transgenic mice differentially affects atherogenesis and established plaques","volume":"100","author":"Stoneman","year":"2007","journal-title":"Circ Res"},{"key":"B127","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagli ozin and renal outcomes in type 2 diabetes and nephropathy (CREDENCE)","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"B128","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature09922","article-title":"Gut ora metabolism of phosphatidylcholine and cardiovascular disease","volume":"472","author":"Wang","year":"2011","journal-title":"Nature"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"B130","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1161\/ATVBAHA.114.303887","article-title":"Oxidized LDL induces long-term proin ammatory cytokine production via epigenetic reprogramming","volume":"34","author":"Bekkering","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 Inhibitors for primary and secondary prevention of cardiovascular outcomes: meta-analysis","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"B132","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1161\/CIRCRESAHA.114.302523","article-title":"T cell and macrophage dynamics in plaque in ammation","volume":"114","author":"Sage","year":"2014","journal-title":"Circ Res"},{"key":"B133","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.cell.2016.02.011","article-title":"TMAO Enhances platelet hyperreactivity and thrombosis risk","volume":"165","author":"Zhu","year":"2016","journal-title":"Cell"},{"key":"B134","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature09922","article-title":"Gut ora metabolism of phosphatidylcholine promotes cardiovascular disease","volume":"472","author":"Wang","year":"2011","journal-title":"Nature"},{"key":"B135","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER)","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"B136","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa2415818","article-title":"Lepodisiran (ALPACA)","volume":"392","author":"Nissen","year":"2025","journal-title":"N Engl J Med"},{"key":"B137","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1056\/NEJMoa1600176","article-title":"Cholesterol lowering in intermediate-risk persons without cardiovascular disease (HOPE-3)","volume":"374","author":"Yusuf","year":"2016","journal-title":"N Engl J Med"},{"key":"B138","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower LDL cholesterol beginning early in life on risk of coronary heart disease: mendelian randomization","volume":"60","author":"Ference","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nm.3145","article-title":"Intestinal microbiota metabolism of L-carnitine promotes atherosclerosis","volume":"19","author":"Koeth","year":"2013","journal-title":"Nat Med"},{"key":"B140","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1001\/jama.2024.24017","article-title":"Muvalaplin: oral inhibitor of lp(a) formation","volume":"333","author":"Nicholls","year":"2025","journal-title":"JAMA"},{"key":"B141","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1056\/NEJMoa1701488","article-title":"Cardiovascular safety and efficacy of bococizumab in high-risk patients (SPIRE)","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"B142","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur Heart J"},{"key":"B143","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.cell.2016.02.011","article-title":"Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk","volume":"165","author":"Zhu","year":"2016","journal-title":"Cell"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1790509\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T04:38:24Z","timestamp":1776832704000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1790509\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":143,"alternative-id":["10.3389\/fcvm.2026.1790509"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1790509","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"article-number":"1790509"}}